BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Frequently asked questions
What sector does BioLife Solutions Inc (BLFS) operate in?
BioLife Solutions Inc belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is BioLife Solutions Inc (BLFS) current stock price?
As of the latest data, BioLife Solutions Inc stock price is $37.19, with a previous close of $37.10. BioLife Solutions Inc gained $0.09 in the last trading session, representing a 0.24% increase.
What is BioLife Solutions Inc (BLFS) current market capitalization?
BioLife Solutions Inc market cap is approximately 1.82 billion.
What is BioLife Solutions Inc (BLFS) Earnings Per Share (EPS)?
The trailing EPS is $1.00, and the forward EPS is $0.33.
What is BioLife Solutions Inc (BLFS) Price-to-Earnings (P/E) ratio?
BioLife Solutions Inc current P/E ratio is 37.19, with a forward P/E of 112.7.
What is BioLife Solutions Inc (BLFS) EBITDA?
BioLife Solutions Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 2.91 million.
Does BioLife Solutions Inc (BLFS) pay dividends?
No. BioLife Solutions Inc does not pay a dividend.
How did BioLife Solutions Inc (BLFS) perform in its most recent earnings report?
In the last report (June 30, 2026), BioLife Solutions Inc posted an EPS surprise of 500% and a revenue surprise of 1.06%.
What is BioLife Solutions Inc (BLFS) beta (volatility) score?
BioLife Solutions Inc has a beta of 1.896, suggesting it is more volatile than the market.